{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"24.200","floor":"17.800"},"ipodate":{"start":"2018-06-22 00:00:00","end":"2018-06-27 00:00:00"},"minimumcapital":"4888.77","subscribed":"35.24","marketcap":"69.09億","H_marketcap":"17.27億","pe":"21.48","codesrate":"80.01","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01763/LTN20180622030_C.pdf","ipopricing":"21.600","resultdate":"2018-07-05 00:00:00","enddate":"2018-06-27 00:00:00","listeddate":"2018-07-06 00:00:00","issuenumber":"7996.87萬","issuenumberhK":"2399.08萬","issuenumberother":"5597.79萬","grayprice":"19.86","sponsors":"中國國際金融香港證券有限公司","raisemoney":"160951.00萬","use":"1、約41.7%所得款項凈額或約671.17百萬港元預期用于投資分別位于河北省香河及四川省成都市的兩個顯像診斷及治療用放射性藥品生產及研發基地，以提升我們的生產及研發能力；\n2、約4.7%所得款項凈額或約75.65百萬港元預期用于建立四間生產及分銷附屬公司，以主要于中國生產及分銷锝[99mTc]標記注射液及氟[18F]脫氧葡糖注射液；\n3、約5.9%所得款項凈額或約94.96百萬港元預期用于在廣東省深圳市及安徽省桐城市建立新生產設施，以擴充尿素呼氣試驗藥盒及測試儀的產能；\n4、約17.7%所得款項凈額或約284.88百萬港元預期用于投資研發多種顯像診斷及治療用放射性藥品、放射源產品的原材料、醫用放射性同位素及尿素呼氣試驗產品及相關原材料；\n5、約20.0%所得款項凈額或約321.90百萬港元預期用于選擇性收購；\n6、約10.0%所得款項凈額或約160.95百萬港元預期用作營運資金及一般企業用途。","shares":200,"leadagent":"中國國際金融香港證券有限公司,中信里昂證券有限公司,農銀國際證券有限公司,中信建投(國際)融資有限公司","bookrunners":"中國國際金融香港證券有限公司,中信里昂證券有限公司,農銀國際融資有限公司","coordinator":"中國國際金融香港證券有限公司,中信里昂證券有限公司","firstDayOpen":"20.00","IsEiio":0,"Interestdays":8,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"中國國際金融香港證券有限公司","code":"E01763","name":"中國同輻","fullname":"中國同輻股份有限公司"},"institutioninfo":{"principaloffice":"中國北京市西城區三里河南四巷1號","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"孟琰彬","secretary":"桂友泉,甘美霞","telephone":"(8610) 6852 2774 ","substantialshareholders":"原子能院(18.30%),核動力院(14.69%),中核基金(5.87%)","principalactivities":"公司是中國同位素及輻照技術應用領域的領軍企業,主要從事診斷及治療用放射性藥品及醫用和工業用放射源產品的研究、開發、制造及銷售,亦提供輻照滅菌服務及伽瑪射線輻照裝置的設計、制造及安裝的EPC服務，亦向醫院及其他醫療機構提供獨立醫學檢驗實驗室服務。","website":"http://www.china-isotope.com"},"managerinfo":[{"managername":"孟琰彬","post":"董事長兼執行董事","rankno":1},{"managername":"武健","post":"總經理兼執行董事","rankno":2},{"managername":"杜進","post":"總工程師兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"通程控股有限公司","shareholding":"11,906,400.0","percentage":14.89,"ReleaseDate":"2019-01-06 00:00:00","relatedparty":"上海實業控股有限公司","subsidiary":["通程控股有限公司"],"InverstorType":"公司"},{"institutionname":"北京工業發展投資管理有限公司","shareholding":"10,899,000.0","percentage":13.63,"ReleaseDate":"2019-01-06 00:00:00","relatedparty":"北京市國有資產經營有限責任公司","subsidiary":["北京工業發展投資管理有限公司"],"InverstorType":"公司"},{"institutionname":"中國國有企業結構調整基金股份有限公司","shareholding":"8,155,000.0","percentage":10.2,"ReleaseDate":"2019-01-06 00:00:00","relatedparty":"國務院國資委","subsidiary":["中國誠通控股集團有限公司","中國國有企業結構調整基金股份有限公司","中國機械工業集團有限公司","中國商用飛機有限責任公司","中國西電集團公司"],"InverstorType":"公司"},{"institutionname":"上海醫藥(香港)投資有限公司","shareholding":"8,006,000.0","percentage":10.01,"ReleaseDate":"2019-01-06 00:00:00","relatedparty":"上海醫藥集團股份有限公司","subsidiary":["上海醫藥(香港)投資有限公司","上藥國際供應鏈有限公司"],"InverstorType":"公司"}],"TotalShareholdingPercentage":48.73},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":517}